Regeneron Pharmaceuticals (REGN) fundamentals: P/E, valuation, undervalued?
Regeneron Pharmaceuticals · Health Care · ref. ETF XLV · price $807.71
In short — Regeneron Pharmaceuticals trades at 20.2× earnings (P/E), 13.3× forward, with a net margin of 27.9 % and revenue growth of +17 %. Read: Cheap for the growth (P/E 13 for ~17% growth (PEG 0.8)).
Is Regeneron Pharmaceuticals stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$807.71+39.4% over range
Aug 28, 25low $555.51 · high $840.84Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
71% recommend buying · 17 analysts
Valuation : Cheap for the growth — P/E 13 for ~17% growth (PEG 0.8)
Valuation
20.2
P/E (price/earnings)
13.3
Forward P/E
—
PEG
2.6
Price/book (P/B)
$83.2B
Market cap
40.06
EPS
Profitability & growth
27.9 %
Net margin
+17 %
Revenue growth
-5 %
Earnings growth
$2.7B
Total debt
Regeneron Pharmaceuticals income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2022 | $12.2B | $4.3B | 35.6 % |
| 2023 | $13.1B | $4.0B | 30.1 % |
| 2024 | $14.2B | $4.4B | 31.1 % |
| 2025 | $14.3B | $4.5B | 31.4 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Regeneron Pharmaceuticals's P/E and is the stock undervalued? What's a good P/E?
Regeneron Pharmaceuticals's P/E is 20.2 (forward 13.3). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Cheap for the growth".
Is Regeneron Pharmaceuticals profitable?
Regeneron Pharmaceuticals has a net margin of 27.9 % (EPS 40.06). The company is profitable.
Is REGN stock expensive?
Our read: "Cheap for the growth" — P/E 13 for ~17% growth (PEG 0.8). Cross-check with growth and sector.
💬 A question about Regeneron Pharmaceuticals? The JPI assistant answers using our backtest data.
Keep exploring Regeneron Pharmaceuticals